BioNTech (NASDAQ:BNTX) Issues Earnings Results

BioNTech (NASDAQ:BNTX – Get Rating) posted its earnings results on Monday. The company reported $15.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.16 by $5.87, reports. BioNTech had a return on equity of 142.70% and a net margin of 54.20%. The company had revenue of $6.37 billion for the quarter, compared to analysts’ expectations of $4.50 billion. During the same period last year, the business posted $5.29 earnings per share. The firm’s quarterly revenue was up 211.2% compared to the same quarter last year.

Shares of BioNTech stock traded up $5.75 during trading on Wednesday, hitting $150.18. 30,695 shares of the stock traded hands, compared to its average volume of 1,943,112. The stock has a market cap of $37.07 billion, a P/E ratio of 3.25 and a beta of -0.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.18 and a current ratio of 4.33. BioNTech has a twelve month low of $121.32 and a twelve month high of $464.00. The company has a fifty day moving average price of $157.49 and a two-hundred day moving average price of $205.50.

The company also recently declared a — dividend, which will be paid on Friday, June 17th. Stockholders of record on Friday, June 3rd will be issued a dividend of $1.5342 per share. The ex-dividend date is Thursday, June 2nd. This represents a dividend yield of 1.1%.

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. JustInvest LLC acquired a new position in shares of BioNTech during the fourth quarter worth approximately $254,000. Wells Fargo & Company MN lifted its holdings in shares of BioNTech by 7.0% during the fourth quarter. Wells Fargo & Company MN now owns 84,929 shares of the company’s stock worth $21,895,000 after buying an additional 5,555 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of BioNTech by 127.2% during the fourth quarter. Deutsche Bank AG now owns 621,933 shares of the company’s stock worth $160,335,000 after buying an additional 348,243 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of BioNTech by 59.8% during the fourth quarter. Parametric Portfolio Associates LLC now owns 1,895 shares of the company’s stock worth $489,000 after buying an additional 709 shares during the last quarter. Finally, Boston Private Wealth LLC lifted its holdings in shares of BioNTech by 6.9% during the fourth quarter. Boston Private Wealth LLC now owns 1,936 shares of the company’s stock worth $499,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 14.42% of the company’s stock.

A number of equities research analysts recently weighed in on BNTX shares. Redburn Partners upgraded shares of BioNTech from a “sell” rating to a “neutral” rating in a research note on Tuesday, February 1st. HC Wainwright cut their price objective on shares of BioNTech from $339.00 to $298.00 and set a “buy” rating on the stock in a research note on Tuesday, April 12th. Morgan Stanley lowered their target price on BioNTech from $217.00 to $197.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Canaccord Genuity Group lowered their target price on BioNTech from $450.00 to $300.00 and set a “buy” rating on the stock in a report on Tuesday, April 5th. Finally, Zacks Investment Research lowered BioNTech from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 27th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $259.59.

About BioNTech (Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Articles